JP2020524689A - Ｐａｉ−１過剰発現に関連する状態のプラスミノーゲン処置 - Google Patents

Ｐａｉ−１過剰発現に関連する状態のプラスミノーゲン処置 Download PDF

Info

Publication number
JP2020524689A
JP2020524689A JP2019570806A JP2019570806A JP2020524689A JP 2020524689 A JP2020524689 A JP 2020524689A JP 2019570806 A JP2019570806 A JP 2019570806A JP 2019570806 A JP2019570806 A JP 2019570806A JP 2020524689 A JP2020524689 A JP 2020524689A
Authority
JP
Japan
Prior art keywords
plasminogen
pai
disease
subject
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524689A5 (enExample
Inventor
リン・ギャニオン
ブリジット・グルー
ピエール・ローラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biotherapeutics Inc
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of JP2020524689A publication Critical patent/JP2020524689A/ja
Publication of JP2020524689A5 publication Critical patent/JP2020524689A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019570806A 2017-06-23 2018-06-22 Ｐａｉ−１過剰発現に関連する状態のプラスミノーゲン処置 Pending JP2020524689A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
US62/523,901 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Publications (2)

Publication Number Publication Date
JP2020524689A true JP2020524689A (ja) 2020-08-20
JP2020524689A5 JP2020524689A5 (enExample) 2021-07-29

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570806A Pending JP2020524689A (ja) 2017-06-23 2018-06-22 Ｐａｉ−１過剰発現に関連する状態のプラスミノーゲン処置

Country Status (20)

Country Link
US (1) US11826404B2 (enExample)
EP (1) EP3641888B1 (enExample)
JP (1) JP2020524689A (enExample)
KR (1) KR20200019217A (enExample)
CN (1) CN110831668B (enExample)
AU (1) AU2018287316B2 (enExample)
BR (1) BR112019027229A2 (enExample)
CA (1) CA3068153A1 (enExample)
CL (1) CL2019003789A1 (enExample)
DK (1) DK3641888T3 (enExample)
ES (1) ES2965937T3 (enExample)
FI (1) FI3641888T3 (enExample)
IL (1) IL271470B2 (enExample)
MX (1) MX2019015741A (enExample)
MY (1) MY203136A (enExample)
RU (1) RU2020100080A (enExample)
SG (1) SG11201912813SA (enExample)
TW (1) TWI868051B (enExample)
WO (1) WO2018234861A1 (enExample)
ZA (1) ZA202000280B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TW201822809A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
EP4094775A4 (en) * 2020-02-06 2023-04-19 Talengen International Limited METHODS AND MEDICATIONS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS
JP2023518563A (ja) * 2020-03-24 2023-05-02 タレンゲン インターナショナル リミテッド パーキンソン病を治療する方法及び薬剤
TW202143999A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
WO2021190558A1 (zh) * 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗阿尔茨海默病的方法和药物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502600A (ja) * 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬
JP2016529255A (ja) * 2013-08-13 2016-09-23 サノフイ プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2056865B1 (en) * 2006-08-28 2013-12-25 Omnio Healer AB Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
WO2018108161A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3556380A4 (en) * 2016-12-15 2020-05-13 Talengen International Limited METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502600A (ja) * 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬
JP2016529255A (ja) * 2013-08-13 2016-09-23 サノフイ プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN RESPIRATORY JOURNAL, vol. 47, JPN6022028411, 2016, pages 27 - 30, ISSN: 0004988574 *
HEAMOSTASIS, vol. Vol.18, Suppl.1, JPN6019017210, 1988, pages 165 - 175, ISSN: 0004988573 *
血管と脈管, vol. 第１２巻、第４号, JPN6019012093, 1981, pages 493 - 501, ISSN: 0004988572 *

Also Published As

Publication number Publication date
CN110831668A (zh) 2020-02-21
WO2018234861A1 (en) 2018-12-27
EP3641888B1 (en) 2023-10-11
KR20200019217A (ko) 2020-02-21
IL271470B2 (en) 2025-07-01
MY203136A (en) 2024-06-10
RU2020100080A (ru) 2021-07-23
SG11201912813SA (en) 2020-01-30
DK3641888T3 (da) 2024-01-02
AU2018287316B2 (en) 2024-09-19
TWI868051B (zh) 2025-01-01
FI3641888T3 (fi) 2023-12-19
US11826404B2 (en) 2023-11-28
BR112019027229A2 (pt) 2020-07-07
IL271470B1 (en) 2025-03-01
CN110831668B (zh) 2024-04-12
CL2019003789A1 (es) 2020-07-10
RU2020100080A3 (enExample) 2021-11-02
MX2019015741A (es) 2020-11-11
ES2965937T3 (es) 2024-04-17
TW201904990A (zh) 2019-02-01
ZA202000280B (en) 2021-08-25
CA3068153A1 (en) 2018-12-27
IL271470A (en) 2020-01-30
US20210330761A1 (en) 2021-10-28
AU2018287316A1 (en) 2020-02-06
EP3641888A1 (en) 2020-04-29
EP3641888A4 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
JP2020524689A (ja) Ｐａｉ−１過剰発現に関連する状態のプラスミノーゲン処置
JP2021059549A (ja) プラミノーゲンを含む医薬組成物及びその使用
ES2676422T3 (es) Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
WO2012006516A2 (en) Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke
JP2025134782A (ja) 医薬製剤およびストック溶液
US20210386777A1 (en) Gas mixtures containing low concentrations of xenon and argon provide neuroprotection without inhibiting the catalytic activity of thrombolytic agents
JP5536198B2 (ja) 糖尿病性ケトアシドーシスを治療するための方法および組成物
Tang et al. Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
US20180200330A1 (en) Compositions and Methods for the Treatment of Diseases Related to the Renin-Angiotensin-System
HK40029531B (en) Plasminogen treatment of conditions associated with pai-1 overexpression
HK40029531A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
JP6289511B2 (ja) 羊水塞栓の治療剤
US20240199703A1 (en) Procoagulant peptides and use thereof
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
CN113301907A (zh) 用于治疗和/或改善伴有凝血障碍的败血症的药物
ULC et al. Pr MYLAN-LISINOPRIL
EP2014296A1 (en) Novel strategies for increasing the reperfusion in obstructed blood vessel
JP2014162789A (ja) 羊水塞栓症治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230214